About Advaccine

Beijing Advaccine Biotechnology Co., Ltd. is an innovative vaccine company with a high-value prophylactic and therapeutic vaccine pipeline driven by in-house developed technology platforms.
To date, our pipeline consists of potential first-in-class key assets developed to address diseases caused by SARS-CoV-2, respiratory syncytial virus (RSV) and hepatitis B virus (HBV), which are diseases with huge unmet medical needs. We are also developing vaccine candidates in preclinical stage covering viral-related oncology, as well as neoantigen therapeutic vaccines and tumor-associated antigen therapeutic vaccines.
  • Company Building

  • Enterprise Development History

  • Enterprise Culture Wall

  • Company Building

  • Enterprise Development History

  • Enterprise Culture Wall

我们的团队
Milestone
  • October 2016
    Advaccine completed the pilot test for ADV110.
  • February 2017
    Suzhou Advaccine, our principal operating subsidiary, established.
  • March 2017
    We completed Round I Investment and raised approximately RMB20 million.
  • July 2018
    We initiated the Phase I clinical trial of ADV110 in Australia.
  • November 2019
    We successfully completed the Phase I clinical trial of ADV110.
  • January 2020
    We entered into a memorandum of understanding with Inovio relating to the initiation of co-development of pGX9501/INO4800 against COVID-19.
  • February 2020
    We completed the Round II Investment and raised approximately RMB40 million.
  • June 2020
    We completed the Round III Investment and raised approximately RMB42 million.
  • July 2020
    We obtained the umbrella approval for initiation of Phase I/II clinical trials of pGX9501 from the NMPA.
  • September 2020
    We initiated the Phase I clinical trial of pGX9501 and also received the approval for the commencement of Phase II clinical trial of ADV110 in Australia.We acquired Suzhou Si’ao with a manufacturing center of over 18,000 square meters.
  • November 2020
    We received an approval letter from the Ethics Committee of Jiangsu Provincial Centre for Disease Control and Prevention for the commencement of a Phase II clinical trial of pGX9501. We completed the Round IV Investment and raised approximately RMB220 million.
  • December 2020
    We commenced the Phase II clinical trial of pGX9501 and successfully completed the enrolment as well as the first dosing of all planned trial subjects. We entered into a collaboration agreement with Inovio relating to joint development, manufacturing and commercialization of pGX9501/INO4800. Our Company was converted into a joint stock company. Suzhou Advaccine was accredited as a “High- and NewTechnology Enterprise”.
  • March 2021
    We completed the Round V Investment and raised approximately RMB432 million.